---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Co-prescribed/Concomitant therapies. Topics: Background therapies permitted at a stable dose in NATiV3: GLP-1 receptor agonists, SGLT2 inhibitors, vitamin E, and statins; Therapies excluded in NATiV3: approved NASH or obesity treatment, insulin, thiazolidinediones, and fibrates; Company position: NATiV3 assesses lanifibranor with GLP-1 receptor agonists and SGLT2 inhibitors; Combination with empagliflozin in LEGEND: no further study planned. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Background therapies permitted at a stable dose in NATiV3: GLP-1 receptor agonists, SGLT2 inhibitors, vitamin E, and statins

> “Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months”
> “Statins: for at least 3 months”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “Patients under a stable dose of GLP-1-RA for at least 3 months prior to screening can be included”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.12-2"></a>

### Therapies excluded in NATiV3: approved NASH or obesity treatment, insulin, thiazolidinediones, and fibrates

> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current treatment with insulin”
> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.12-3"></a>

### Company position: NATiV3 assesses lanifibranor with GLP-1 receptor agonists and SGLT2 inhibitors

> “NATiV3 uniquely positioned to assess lanifibranor in combination with GLP-1 and SGLT2 inhibitors: Reflecting the evolving treatment paradigm and supporting its potential as a backbone therapy.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.12-4"></a>

### Combination with empagliflozin in LEGEND: no further study planned

> “The LEGEND trial was intended to demonstrate proof of concept and the potential additional benefits of the combination between lanifibranor and empagliflozin and the possibility to address the weight gain observed in some patients treated with lanifibranor alone.”
> “We do not expect to further study the combination of lanifibranor and empagliflozin but expect to include the safety data from the LEGEND trial in a potential submission for marketing approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
